1． Suzuki Y, Mori T, Yokoyama M, Kim S, Momose H, Matsuki R, Kogure M, Nakazato T, Abe N, Isayama H, Nakazawa T, Notohara K, Tanaka A, Tsuyuguchi T, Tazuma S, Takikawa H, Sugiyama M.
A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort., J Gastroenterol, 53（7）：854-860, 2018
2． Tanaka A.
Is HBV-associated intrahepatic cholangiocarcinoma preventable with antiviral treatment?, Clin Gastroenterol Hepatol, 16（6）：821-822, 2018
3． Natsume M, Watanabe K, Matumoto S, Naruge D, Hayashi K, Furuse J, Kawamura M, Jinno H, Sano K, Fukushima R, Aruga E, Hashiguchi Y, Tanaka A, Takikawa H, Eguchi K, Seki N.
Factors influencing cancer patients’choice of palliative care place., J Palliative Medicine, 21（6）：751- 765, 2018
4． Tanaka A, Hirohara J, Nakano T, Yagi M, Namisaki T, Yoshiji H, Nakanuma Y, Takikawa H; Japan PBC Study Group (JPBCSG).
Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis., Hepatol Res, 48（9）：727-734, 2018
5． Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep CN, Tsuneyama K, Kage M, Nakano M, Kan JH, Koike K, Zeniya M, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H, the Japan Autoimmune Hepatitis Study Group (JAIHG).
Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey., J Gastroenterol, 53（9）：1079-1088, 2018
6． Ikeda H, Watanabe T, Matsumoto N, Hiraishi T, Nakano N, Noguchi Y, Hattori N, Shigefuku R, Matsunaga K, Ishii T, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M and Itoh F.
Treatment with Daclatasvir and Asunaprevir for 24 weeks improves health-related quality of life in Japanese patients infected with hepatitis C virus., JGH open, 14（2(3)）：87-92, 2018
7． Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG).
Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study., J Gastroenterol, 53（10）：1151-1158, 2018
8． Nishida N, Aiba Y, Hitomi Y, Kawashima M, Kojima K, Kawai Y, Ueno K, Nakamura H, Yamashiki N, Tanaka T, Tamura S, Mori A, Yagi S, Soejima Y, Yoshizumi T, Takatsuki M, Tanaka A, Harada K, Shimoda S, Komori A, Eguchi S, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, TokunagaK, Nakamura M. NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population., Sci Rep, 23（8(1)）：8071-, 2018
9． Deneau MR, Mack C, Abdou R, Amin M, Amir A, Auth M, Bazerbachi F, Broderick AM, Chan A, DiGuglielmo M, El-Matary W, El-Youssef M, Ferrari F, Furuya KN, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Martinez M, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Valentino PL, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Miloh T.
Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis., Hepatol Commun, 25（2(11)）：1369-1378, 2018
10． Tanaka A, Leung PSC, Gershwin ME.
Pathogen infections and primary biliary cholangitis., Clin Exp Immunol, 195（1）：25-34, 2019
11． Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, Kikuchi K, Yasunaka T, Takaki A, Ueno Y, Honda A, Matsuzaki Y, Takikawa H.
Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis., Sci Rep, 22（8(1)）：12542-, 2018
12． Tanaka A, Leung PSC, Gershwin ME.
Evolution of our understanding of PBC., Best Pract Res Clin Gastroenterol, 34-35：3-9, 2018
13． Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group.
Clinical guidelines for primary sclerosing cholangitis 2017., J Gastroenterol, 53（9）：1006-1034, 2018 14． Takahashi A, Moriya K, Ohira H，Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Yoshiji H, Goto A, Tanaka A, Takikawa H,
The Autoimmune Hepatitis Study Group, a sub group of the Intractable Hepato-Biliary Disease Study Group in Japan.
Health-Related Quality of Life in patients with autoimmune hepatitis: a questionnaire survey., PLoS One, 13（10）：e0204772, 2018
15． Moritoki Y, Tsuneyama K, Nakamura Y, Kikuchi K, Shiota A, Ohsugi Y, Lian ZX, Zhang W, Yang GX, Ueki S, Takeda M, Omokawa A, Saga T, Watanabe D, Miura M, Ueno Y, Leung PSC, Tanaka A, Gershwin ME, Hirokawa M.
Anti-drug antibodies against a novel humanized anti-CD20 antibody impair its therapeutic effect on primary biliary cholangitis in human CD20- and Fc γ R-expressing mice., Front Immunol, 9：2534,2018
16． Rosa R, Cristoferi L, Tanaka A, Invernizzi P.
Geoepidemiology and (epi-)genetics in primary biliary cholangitis., Best Practice & Research Clinical Gastroenterology, 34-35：11-15, 2018
17． Tanaka A, Leung PSC, Gershwin ME.
The Genetics and Epigenetics of Primary Biliary Cholangitis., Clin Liver Dis, 22（3）：443-455, 2018 18． Uchino K, Tateishi R, Asaoka Y, Koike K, et al.
Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation., PLoS One, 13（7）：e0200943, 2018
19． Enooku K, Asaoka Y, Koike K, et al.
Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients., J Gastroenterol, 53（12）：1261-1275, 2018
20． Tanaka A, Gershwin ME.
Environmental Basis of Autoimmunity., Exp Biol Med (Maywood)., 243（2）：184-189, 2018
21． Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H, Japan AIH Study Group (JAIHSG).
Nonalcoholic fatty liver disease in patients with autoimmune hepatitis., JGH Open., 2（2）：54-58, 2018
22． 厚生労働科学研究費補助金 難治性疾患政策研究事業 「難治性の肝・胆道疾患に関する調査研究」班自己免疫性肝炎分科会・原発性胆汁性胆管炎分科会
改訂自己免疫性肝炎・原発性胆汁性胆管炎ガイドライン, 肝臓, 59（4）：211-216, 2018
23． 田 中 篤
原発性硬化性胆管炎（PSC）のup-to-date, 胆道, 50（32）：241-250, 2018
24． 大平弘正、田中 篤
自己免疫性肝炎におけるアザチオプリンの公知申請について, 肝臓, 59（11）：653-654, 2018
25． Maruyama K, Yamamoto T, Aoyagi H, Isono A, Abe K, Kodashima S, Kita H, Watari Y, Kozuma K Difference between the upper and the lower gastrointestinal bleeding in patients taking non-vitamin K oral anticoagulants, BioMed Res Int, Article ID7123607, 2018
26． Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Akishita M, Hasebe N, Kario K, Mizokami Y, Nagata K, Nakamura M, Terauchi Y, Yamamoto T, Teramukai S, Kimura T, Kaburagi J, Takita A
Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry, J Cardiol, 72（4）：300-306, 2018
27． Abe K, Yanagisawa D, Numakura S
Esophageal neuroendocrine carcinoma presented as a flat depressed lesion. Clin Gastroenterol Hepatol 2018 May 3. pii: S1542-3565(18)30464-6.
28． Zobair M. Younossi, Tanaka A, Eguchi Y, L Henry, Beckerman R, Mizokami M.
Treatment of Hepatitis C Virus Leads to Economic Gain Related to Reduction in Cases of Hepatocellular Carcinoma (HCC) and Decompensated Cirrhosis in Japan., J Viral Hepat, 25（8）：945-951, 2018
29． 田 中 篤
日本肝臓学会B 型肝炎治療ガイドラインupdate, Mebio, 35（1）：39-45, 2018
30． 田 中 篤
肝癌の主な病因とその治療 原発性胆汁性胆管炎, 日本臨床, 76（2）：310-314, 2018
31． 田 中 篤
硬化性胆管炎の診療の進歩, 別冊 医学のあゆみ「胆膵疾患診療の進歩」, 111, 2018
32． 田 中 篤
自己免疫性肝疾患の最新情報, 医学のあゆみ, 264（8）：685, 2018
33． 田中 篤、小池和彦
C 型肝炎治療の現状と今後の課題, 日本医事新報, 489846-51, 2018
34． 田 中 篤
血中B 型肝炎ウイルスDNA 量の単位表記, Medical Practice, 35（5）：811, 2018
35． 田 中 篤
日本肝臓学会C 型肝炎ガイドライン －改訂のポイント‐ , 消化器・肝臓内科, 3（4）：389-396, 2018
36． 田 中 篤
IgG4 関連硬化性胆管炎, 日本医師会雑誌, 147（2）：244, 2018
37． 田 中 篤
ゲノタイプ 2 型のC 型肝炎治療－グレカプレビル / ピブレンタスビル配合剤、ソホスブビル + リバビリン、ソホスブビル/ レジパスビル配合錠の選択, 消化器の臨床, 21（2）：109-113, 2018
38． 田 中 篤
IgG4 関連硬化性胆管炎, 日本医師会雑誌, 147（2）：244, 2018
39． 田 中 篤
原発性胆汁性胆管炎 －残された課題, 肝臓クリニカルアップデート, 4（1）：25-30, 2018
40． 田 中 篤
原発性胆汁性胆管炎, 消化器・肝臓内科, 3（6）：607-611, 2018
41． 田 中 篤
C 型肝炎患者におけるHBV 再活性化の病態と対応, 日本医事新報, No.4917p49-53, 2018
42． 田 中 篤
自己免疫性肝疾患の現状と将来, 日本医事新報, No.4992p48-53, 2018
43． 田 中 篤
薬物性肝障害の診断のコツ ほかの肝障害とどう鑑別すればいいの？, レジデントノート, 20（10）：1681- 1688, 2018
44． 田 中 篤
IgG4 関連硬化性胆管炎, 消化器外科, 41（10）：1425-1432, 2018
45． 田 中 篤
原発性胆汁性胆管炎 ～最近の国内共同研究から～, たんじゅうさん, 17（1）：16-17, 2018
46． 山本貴嗣
抗血栓薬と下部消化管出血, 消化器・肝臓内科, 3（4）：371-376, 2018
47． 山本貴嗣
薬剤性消化管傷害の現状と課題, Medical Practice, 35（1）：67-71, 2018
48． 山本貴嗣
高齢者の便秘, 臨床消化器内科, 33（4）：447-451, 2018
49． 山本貴嗣
便秘における漢方薬の使い方, レジデント, 11（1）：22-30, 2018
50． 松田圭二、大野航平、岡田有加、八木貴博、塚本充雄、福島慶久、堀内敦、山田英樹、小澤毅士、島田竜、端山軍、土屋剛史、野澤慶次郎、青柳仁、磯野朱里、阿部浩一郎、小田島慎也、山本貴嗣、橋口陽二郎癌化のサーベイランス, 臨床外科, 73（12）：1316-1321, 2018
51． Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, Inui K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno T, Yoshida M.
Clinical practice guidelines for IgG4-related sclerosing cholangitis., J Hepatobiliary Pancreat Sci., 26（1）：9-42, 2019
52． Tanaka A, Leung PSC, Gershwin ME.
The Genetics of Primary Biliary Cholangitis., Curr Opin Gastroenterol, 35（2）：93-98, 2019
53． Younossi Z, Henry L, Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim, YS, Dan, YY, Yu, ML, Stepanova, M. Systematic Review with Meta-Analysis: The Extrahepatic Manifestations in Chronic Hepatitis C Virus- Infected Patients in East Asia., Aliment Pharmacol Ther, 49（6）：644-653, 2019
54． Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga- Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.
POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33., Sci Rep, 9（1）：102, 2019
55． Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.
An analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan., Hepatol Res, 49（1）：105-110, 2019
56． Nakagomi R, Tateishi R, Asaoka Y, Koike K, et al.
Liver stiffness measurements in chronic hepatitis C: treatment evaluation and risk assessment., J Gastroenterol Hepatol, 34（5）：921-928, 2019
57． Nishibatake Kinoshita M, Minami T, Tateishi R, Asaoka Y, Koike K, et al.
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon- based therapy., J Hepatol, 70（1）：78-86, 2019
58． Komatsuda S, Kamata M, Abe K, Yamamoto T, et al
Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation, J Dermatol, 4673-75, 2019
59． Tanaka A.
IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis. , Gut Liver., 13（3）：300-307, 2019
60． Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, Inui K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno T, Yoshida M.
Clinical practice guidelines for IgG4-related sclerosing cholangitis., J Hepatobiliary Pancreat Sci., 26（1）：9-72, 2019
61． Tanaka A, Leung PSC, Gershwin ME.
The Genetics of Primary Biliary Cholangitis. , Curr Opin Gastroenterol, 35（2）：93-98, 2019
62． Younossi Z, Henry L, Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim, YS, Dan, YY, Yu, ML, Stepanova, M. Systematic Review with Meta-Analysis: The Extrahepatic Manifestations in Chronic Hepatitis C Virus- Infected Patients in East Asia., Aliment Pharmacol Ther, 49（6）：644-653, 2019
63． Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga- Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.
POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33., Sci Rep, 9（1）：102, 2019
64． Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.
An analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan., Hepatol Res., 49（1）：105-110, 2019
65． Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, Namisaki T, Hashimoto N, Kawata K, Takahashi A, Ninomiya M, Kang JK, Arakawa M, Yamagiwa S, Joshita S, Umemura T, Sato K, Kaneko A, Kikuchi K, Itakura J, Nomura T, Kakisaka K,21 Fujii H, Kawada N, Takikawa Y, Masaki T, Ohira H, Mochida S, Yoshiji H, Iimuro S, Matsuzaki Y, Takikawa H, and Japan PBC Study Group (JPBCSG).
Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis., Hepatology, doi: 10.1002/hep.30552., 2019
66． Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H.
An increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan., Hepatol Res., 49（8）：881-889, 2019
67． Tanaka A.
Emerging novel treatments for autoimmune liver diseases., Hepatol Res., 49（5）：489-499, 2019 68． Tanaka A.
IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis. , Gut and Liver., 13（3）：300- 307, 2019
69． Tanaka A.
Immunoglobulin G4-related sclerosing cholangitis: A review., J Dig Dis. , 20（7）：357-362, 2019
70． Umetsu S, Notohara K, Nakazawa T, Tsunoda T, Sogo T, Komatsu H, Tanaka A, Tazuma S, Takikawa H, Inui A, Fujisawa T.
The long-term outcomes of pediatric-onset primary sclerosing cholangitis: a single center experience in Japan., Hepatol Res, doi: 10.1111/hepr.13421., 2019
71． Beretta-Piccoli BT, Mieli-Vergani G, Vergani D, Vierling J, Adams D, Alpini G, Bañales Asurmendi J, Beuers U, Björnsson E, Bowlus CL, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley E, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, ME Gershwin.
The Challenges of Primary Biliary Cholangitis: What is new and what needs to be done., J Autoimmunity, (in press),
72． Chang C, Tanaka A, Gershwin ME.
The Use of Biologics in the Treatment of Autoimmune Liver Disease., Expt Opi Invest Drugs, (in press), 73． Tanaka A, Leung P, Kono H, Gershwin ME.
Recurrence of Disease Following Organ Transplantation in Autoimmune Liver Disease and Systemic Lupus Erythematosus., Cellular Immunol, (in press),
74． Tanaka A.
Autoimmune Hepatitis: 2019 Update., Gut and Liver, (in press), 75． Chang C, Tanaka A, Gershwin ME.
Unmet needs in autoimmune liver diseases., J Dig Dis, (in press),
76． Miki A, Okamura T, Aoyagi H, Isono A, Abe K, Kodashima S, Yamamoto T
Impact of varenicline on gastric emptying of liquids: -possible cause of nausea-, Jpn J Appl Physiol, (in press),
77． Matsuda K, Ohno K, Okada Y, Yagi T, Tsukamoto M, Fukushima Y, Akahane T, Horiuchi A, Shimada R, Ozawa T, Hayama T, Okamoto K, Tsuchiya T, Tamura J, Iinuma H, Nozawa K, Aoyagi H, Isono A, Abe K, Kodashima S, Yamamoto T, Kita H, Sasajima Y, Kondo F, Hashiguchi Y
Efficacy and tolerability of oral budesonide in Crohn’s disease patients with attenuated response to anti TNF- α antibody drug – a single institutional study, Annals of Biomedical Research, (in press),
ページ上部に戻る
